Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

[
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
[og_img]
https://www.investing.com/news/press-releases/replimune-presents-new-analyses-from-the-ignyte-study-of-rp1-plus-nivolumab-in-antipd1-failed-melanoma-at-the-2025-american-society-of-clinical-oncology-asco-annual-meeting-93CH-4074463


Investing.com